The Sandoz unit of Switzerland-based Novartis (NYSE: NVS) has announced plans to construct a biosimilar development center in Slovenia by 2026, with an investment of approximately USD 90 million. This new project complements an existing generics plant and a planned biologic drugs factory in the country, valued at over USD 400 million, as well as an expansion project in Germany.
Expanding Biosimilar Pipeline and Global Presence
Sandoz, a leader in the biosimilars market, currently boasts eight biosimilars launched to the market and has 24 candidates in its pipeline. The sector is experiencing rapidly rising global demand, driven by efforts to ensure the long-term viability of healthcare systems. This investment in Slovenia aligns with Sandoz’s commitment to meeting the growing demand for biosimilars and enhancing patient access to affordable, high-quality medicines.
Contribution to Healthcare System Viability
The establishment of the biosimilar development center in Slovenia underscores Sandoz’s role in contributing to the sustainability of healthcare systems worldwide. By expanding its biosimilars portfolio and production capabilities, Sandoz is poised to play a significant part in shaping the future of healthcare, providing more cost-effective alternatives to originator biologics and supporting the broader pharmaceutical industry’s evolution.-Fineline Info & Tech
